Syntec Optics Secures New Optics Order For Defense Head-Up Microdisplays

Syntec Optics (NASDAQ:OPTX), a mission-critical supplier of scientific and technical instruments and defense and aerospace optics to OEMs, today announced orders for a new high-resolution, wide-field-of-view, innovative

Syntec Optics (NASDAQ:OPTX), a mission-critical supplier of scientific and technical instruments and defense and aerospace optics to OEMs, today announced orders for a new high-resolution, wide-field-of-view, innovative freeform prism subsystem that makes up high-brightness and high-contrast defense microdisplays used for viewing vital information. These new orders add to orders received for other versions of microdisplay optics already in production. Delivery is scheduled for 2024.

Syntec Optics has been contributing since the initial development and early production orders of such mission-critical lightweight freeform prism sub-systems used in visualization systems that began over a decade ago for aviation pilots.

“I am excited to see how the Syntec Optics team is unique in producing lightweight freeform using advanced manufacturing techniques,” said Sara Hart, Sales Director of Syntec Optics.

“The team here appreciates the opportunity to contribute to a device that significantly increases situational awareness. Freeform prisms require intricate manufacturing techniques, and making them lightweight needs cutting-edge technology,” said Beth Blood, Program Manager at Syntec Optics.

US defense is actively fielding optical systems with advanced visualization techniques, requiring multiple orders of lightweight freeform prisms. Electronics integrated by OEM generate augmented reality information overlays onto these wide-field-of-view OLED micro-displays.

Total
0
Shares
Related Posts
Read More

AstraZeneca, Swedish Orphan Biovitrum And Sanofi Have Updated And Simplified Their Contractual Arrangements Relating To The Development And Commercialization Of Nirsevimab In The US

AstraZeneca, Swedish Orphan Biovitrum AB (publ) (Sobi) and Sanofi have updated and simplified their contractual arrangements relating to the development and commercialisation of nirsevimab in the US. Given the upcoming launch of nirsevimab in the US and other markets, simplification of the prior arrangements clarifies the roles and responsibilities of relevant parties.   

AZN